How Multiparametric Breast MRI Avoids Unneeded Biopsies

Evaluating non-mass enhancement (NME) breast lesions poses a significant clinical challenge for modern radiologists. Therefore, clinicians increasingly rely on advanced imaging techniques to differentiate benign from malignant tissues accurately. Recently, a prospective diagnostic accuracy study evaluated the performance of multiparametric breast MRI in this specific clinical context.

Understanding Multiparametric Breast MRI

This multi-center prospective trial enrolled 351 female patients with BI-RADS 3 to 5 non-mass enhancement lesions. In addition, nine experienced radiologists independently evaluated the examinations to minimize bias. The index test combined dynamic contrast-enhanced imaging with diffusion-weighted imaging and apparent diffusion coefficient measurements. Consequently, the researchers compared these findings directly against histopathological confirmation. The results showed that consensus-based multiparametric MRI achieved an outstanding sensitivity of 98.4% and a specificity of 86.4%. Moreover, the negative predictive value reached an exceptional 97.9%, which remains highly consistent across all BI-RADS categories.

Predictors of Malignancy and Agreement

Furthermore, the investigators identified five independent predictors of malignancy during the statistical analysis. Specifically, Type III washout curves demonstrated the highest odds ratio of 26.84, indicating a strong correlation with cancer. Segmental distribution and Type II plateau curves also served as significant predictors of malignant disease. Similarly, apparent diffusion coefficient values of 1.3 or less and regional distribution predicted malignancy. Importantly, the readers demonstrated almost perfect inter-reader agreement with a kappa value of 0.847. This high level of consensus highlights the reliability of the diagnostic technique.

Clinical Impact on Patient Care

Clearly, these findings carry major implications for clinical practice, particularly in reducing unnecessary breast biopsies. Because non-mass enhancement lesions often present diagnostic dilemmas, clinicians frequently perform biopsies to rule out cancer. However, this study suggests that the excellent negative predictive value of this MRI protocol can safely prevent invasive procedures. Therefore, radiologists can confidently recommend surveillance for low-risk cases, which significantly lowers patient anxiety and healthcare costs. Ultimately, integrating these parameters into daily practice will enhance diagnostic precision and optimize breast cancer management.

Frequently Asked Questions

Q1: What are the main predictors of malignancy in NME breast lesions according to the study?

Specifically, the predictors include Type III washout, segmental distribution, Type II plateau, low ADC values, and regional distribution.

Q2: How accurate is multiparametric breast MRI for differentiating benign from malignant lesions?

The consensus-based MRI protocol achieved an overall accuracy of 92.9%, with 98.4% sensitivity and 86.4% specificity.

Q3: Can this imaging protocol help reduce unnecessary biopsies?

Indeed, the high negative predictive value of 97.9% allows clinicians to rule out cancer and safely avoid unnecessary biopsies.

References

1. Soliman BK et al. Multiparametric MRI for non-mass enhancement breast lesions: a prospective diagnostic accuracy study. Eur Radiol. 2026 May 21. doi: 10.1007/s00330-026-12641-1. PMID: 42166016.
2. Tarigan VN et al. An Updated Systematic Review and Meta-Analysis of Diagnostic Accuracy of Dynamic Contrast Enhancement and Diffusion-Weighted MRI in Differentiating Benign and Malignant Non-Mass Enhancement Lesions. J Clin Med. 2025 Jun 30;14(13):4628. doi: 10.3390/jcm14134628.